Stromedix Wins Patent For Lead Drug

Xconomy Boston — 

Stromedix, a Cambridge, MA-based biotech company, said it has received a U.S. patent that protects its lead drug for fibrosis, STX-100. The patent, U.S. 7,465,449, covers high-affinity monoclonal antibodies and antigen-binding fragments that block a target on cells that is an important regulator of fibrosis and tissue injury. Rebecca described this technology that Stromedix acquired from Biogen Idec back in April.